242 related articles for article (PubMed ID: 17898565)
1. Chimeric Antigen Receptor T Cells and Hematopoietic Cell Transplantation: How Not to Put the CART Before the Horse.
Kenderian SS; Porter DL; Gill S
Biol Blood Marrow Transplant; 2017 Feb; 23(2):235-246. PubMed ID: 27638367
[TBL] [Abstract][Full Text] [Related]
2. Augmentation of anti-tumor immunity by adoptive T-cell transfer after allogeneic hematopoietic stem cell transplantation.
Bleakley M; Turtle CJ; Riddell SR
Expert Rev Hematol; 2012 Aug; 5(4):409-25. PubMed ID: 22992235
[TBL] [Abstract][Full Text] [Related]
3. Can Graft vs. Leukemia Effect Be Uncoupled From Graft vs. Host Disease? An Examination of Proportions.
Krieger E; Toor AA
Front Immunol; 2020; 11():777. PubMed ID: 32425947
[No Abstract] [Full Text] [Related]
4. Defining success with cellular therapeutics: the current landscape for clinical end point and toxicity analysis.
Kean LS
Blood; 2018 Jun; 131(24):2630-2639. PubMed ID: 29728399
[TBL] [Abstract][Full Text] [Related]
5. Planes, Trains, and Automobiles: Perspectives on CAR T Cells and Other Cellular Therapies for Hematologic Malignancies.
Gill S
Curr Hematol Malig Rep; 2016 Aug; 11(4):318-25. PubMed ID: 27136938
[TBL] [Abstract][Full Text] [Related]
6. Personal tumor antigens in blood malignancies: genomics-directed identification and targeting.
Penter L; Wu CJ
J Clin Invest; 2020 Apr; 130(4):1595-1607. PubMed ID: 31985488
[TBL] [Abstract][Full Text] [Related]
7. Graft Versus Leukemia: Current Status and Future Perspectives.
O'Neill AT; Chakraverty R
J Clin Oncol; 2021 Feb; 39(5):361-372. PubMed ID: 33434054
[No Abstract] [Full Text] [Related]
8. Building a Fit for Purpose Clinical Trials Infrastructure to Accelerate the Assessment of Novel Hematopoietic Cell Transplantation Strategies and Cellular Immunotherapies.
Devine SM; Horowitz MM
J Clin Oncol; 2021 Feb; 39(5):534-544. PubMed ID: 33434065
[No Abstract] [Full Text] [Related]
9. New strategies of DLI in the management of relapse of hematological malignancies after allogeneic hematopoietic SCT.
Chang X; Zang X; Xia CQ
Bone Marrow Transplant; 2016 Mar; 51(3):324-32. PubMed ID: 26595077
[TBL] [Abstract][Full Text] [Related]
10. Sirolimus-based graft-versus-host disease prophylaxis promotes the in vivo expansion of regulatory T cells and permits peripheral blood stem cell transplantation from haploidentical donors.
Peccatori J; Forcina A; Clerici D; Crocchiolo R; Vago L; Stanghellini MT; Noviello M; Messina C; Crotta A; Assanelli A; Marktel S; Olek S; Mastaglio S; Giglio F; Crucitti L; Lorusso A; Guggiari E; Lunghi F; Carrabba M; Tassara M; Battaglia M; Ferraro A; Carbone MR; Oliveira G; Roncarolo MG; Rossini S; Bernardi M; Corti C; Marcatti M; Patriarca F; Zecca M; Locatelli F; Bordignon C; Fleischhauer K; Bondanza A; Bonini C; Ciceri F
Leukemia; 2015 Feb; 29(2):396-405. PubMed ID: 24897508
[TBL] [Abstract][Full Text] [Related]
11. Enhanced transduction and replication of RGD-fiber modified adenovirus in primary T cells.
Sengupta S; Ulasov IV; Thaci B; Ahmed AU; Lesniak MS
PLoS One; 2011 Mar; 6(3):e18091. PubMed ID: 21464908
[TBL] [Abstract][Full Text] [Related]
12. T-cell-based therapies for malignancy and infection in childhood.
Ahmed N; Heslop HE; Mackall CL
Pediatr Clin North Am; 2010 Feb; 57(1):83-96. PubMed ID: 20307713
[TBL] [Abstract][Full Text] [Related]
13. Programming tumor-reactive effector memory CD8+ T cells in vitro obviates the requirement for in vivo vaccination.
Klebanoff CA; Yu Z; Hwang LN; Palmer DC; Gattinoni L; Restifo NP
Blood; 2009 Aug; 114(9):1776-83. PubMed ID: 19561320
[TBL] [Abstract][Full Text] [Related]
14. Adoptive transfer of allogeneic tumor-specific T cells mediates effective regression of large tumors across major histocompatibility barriers.
Boni A; Muranski P; Cassard L; Wrzesinski C; Paulos CM; Palmer DC; Gattinoni L; Hinrichs CS; Chan CC; Rosenberg SA; Restifo NP
Blood; 2008 Dec; 112(12):4746-54. PubMed ID: 18799724
[TBL] [Abstract][Full Text] [Related]
15. Immunotherapy for myeloid leukemias: current status and future directions.
el-Shami K; Smith BD
Leukemia; 2008 Sep; 22(9):1658-64. PubMed ID: 18563174
[TBL] [Abstract][Full Text] [Related]
16. T-cell therapy after hematopoietic stem cell transplantation.
Kennedy-Nasser AA; Brenner MK
Curr Opin Hematol; 2007 Nov; 14(6):616-24. PubMed ID: 17898565
[TBL] [Abstract][Full Text] [Related]
17. T cell therapies following hematopoietic stem cell transplantation: surely there must be a better way than DLI?
Kennedy-Nasser AA; Bollard CM
Bone Marrow Transplant; 2007 Jul; 40(2):93-104. PubMed ID: 17502898
[TBL] [Abstract][Full Text] [Related]
18. Antiviral immunity and T-regulatory cell function are retained after selective alloreactive T-cell depletion in both the HLA-identical and HLA-mismatched settings.
Davies JK; Koh MB; Lowdell MW
Biol Blood Marrow Transplant; 2004 Apr; 10(4):259-68. PubMed ID: 15077224
[TBL] [Abstract][Full Text] [Related]
19. Cell therapy: achievements and perspectives.
Bordignon C; Carlo-Stella C; Colombo MP; De Vincentiis A; Lanata L; Lemoli RM; Locatelli F; Olivieri A; Rondelli D; Zanon P; Tura S
Haematologica; 1999 Dec; 84(12):1110-49. PubMed ID: 10586214
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
